Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown
This article was originally published in PharmAsia News
Executive Summary
Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA
You may also be interested in...
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24
Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008
TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference